BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34129878)

  • 1. Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy.
    Wang H; Liu B; Wei J
    Cancer Lett; 2021 Oct; 517():96-104. PubMed ID: 34129878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
    Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
    Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.
    Haworth KB; Arnold MA; Pierson CR; Leddon JL; Kurmashev DK; Swain HM; Hutzen BJ; Roberts RD; Cripe TP
    Pediatr Blood Cancer; 2016 Apr; 63(4):618-26. PubMed ID: 26575538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers.
    Reis B; Attig J; Dziadek S; Graefe N; Heller A; Rieder N; Gomes B
    Front Immunol; 2024; 15():1285049. PubMed ID: 38455061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
    de Vries NL; van de Haar J; Veninga V; Chalabi M; Ijsselsteijn ME; van der Ploeg M; van den Bulk J; Ruano D; van den Berg JG; Haanen JB; Zeverijn LJ; Geurts BS; de Wit GF; Battaglia TW; Gelderblom H; Verheul HMW; Schumacher TN; Wessels LFA; Koning F; de Miranda NFCC; Voest EE
    Nature; 2023 Jan; 613(7945):743-750. PubMed ID: 36631610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
    Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
    Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
    Kagoya Y; Guo T; Yeung B; Saso K; Anczurowski M; Wang CH; Murata K; Sugata K; Saijo H; Matsunaga Y; Ohashi Y; Butler MO; Hirano N
    Cancer Immunol Res; 2020 Jul; 8(7):926-936. PubMed ID: 32321775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules.
    Lhotakova K; Grzelak A; Polakova I; Vackova J; Smahel M
    Oncol Rep; 2019 Dec; 42(6):2826-2835. PubMed ID: 31638243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immune-related role of beta-2-microglobulin in melanoma.
    Wang C; Wang Z; Yao T; Zhou J; Wang Z
    Front Oncol; 2022; 12():944722. PubMed ID: 36046045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies
    Pereira C; Gimenez-Xavier P; Pros E; Pajares MJ; Moro M; Gomez A; Navarro A; Condom E; Moran S; Gomez-Lopez G; Graña O; Rubio-Camarillo M; Martinez-Martí A; Yokota J; Carretero J; Galbis JM; Nadal E; Pisano D; Sozzi G; Felip E; Montuenga LM; Roz L; Villanueva A; Sanchez-Cespedes M
    Clin Cancer Res; 2017 Jun; 23(12):3203-3213. PubMed ID: 28302866
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonstructural Protein 4 of Porcine Reproductive and Respiratory Syndrome Virus Modulates Cell Surface Swine Leukocyte Antigen Class I Expression by Downregulating β2-Microglobulin Transcription.
    Qi P; Liu K; Wei J; Li Y; Li B; Shao D; Wu Z; Shi Y; Tong G; Qiu Y; Ma Z
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28003480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.
    Castro A; Ozturk K; Pyke RM; Xian S; Zanetti M; Carter H
    BMC Med Genomics; 2019 Jul; 12(Suppl 6):107. PubMed ID: 31345234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma.
    Yeon Yeon S; Jung SH; Jo YS; Choi EJ; Kim MS; Chung YJ; Lee SH
    Pathol Res Pract; 2019 Jan; 215(1):209-214. PubMed ID: 30503610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-2 microglobulin knockout K562 cell-based artificial antigen presenting cells for
    Zha S; Li Z; Chen C; Du Z; Tay JC; Wang S
    Immunotherapy; 2019 Aug; 11(11):967-982. PubMed ID: 31218907
    [No Abstract]   [Full Text] [Related]  

  • 17. A simple method to predict protein-binding from aligned sequences--application to MHC superfamily and beta2-microglobulin.
    Duprat E; Lefranc MP; Gascuel O
    Bioinformatics; 2006 Feb; 22(4):453-9. PubMed ID: 16352655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system.
    Ardeniz Ö; Unger S; Onay H; Ammann S; Keck C; Cianga C; Gerçeker B; Martin B; Fuchs I; Salzer U; İkincioğulları A; Güloğlu D; Dereli T; Thimme R; Ehl S; Schwarz K; Schmitt-Graeff A; Cianga P; Fisch P; Warnatz K
    J Allergy Clin Immunol; 2015 Aug; 136(2):392-401. PubMed ID: 25702838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric beta2 microglobulin/CD3zeta polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8(+) T cells.
    Margalit A; Fishman S; Berko D; Engberg J; Gross G
    Int Immunol; 2003 Nov; 15(11):1379-87. PubMed ID: 14565936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.